InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on “Global Gene Therapy for Retinal Diseases Market Assessment – Revenue (US$ Mn) Forecast Till 2030”
According to the latest research by InsightAce Analytic, the global market for gene therapy for retinal diseases was valued at US$ XX Mn and it is expected to reach US$ XX million in 2030, recording a promising CAGR of XX% during the period of 2020-2030.
The most common approach for retinal gene therapy is delivering the normal gene to the retinal cells using a vector, a modified virus engineered to not proliferate or cause structural damage. The genetic retinal disorders can cause blindness or severe vision loss. These disorders are caused due to mutation of genes. The gene therapy helps to stop or slow down progress of retinal disorders. In the recent years, gene therapy for genetic retinal diseases have made major advances. The therapy enhancing cell specific targeting and augmenting the therapeutic effect and limit death of cell. The growing adoption of gene therapy for retinal disorders such as Choroideremia (CHM), Leber congenital amaurosis, Leber’s hereditary optic neuropathy, X-linked retinitis pigmentosa etc. is expected to propel the growth of market in the coming future. The growing research activities to develop gene therapy for retinal diseases is expected to propel the growth of market in the coming years.
Global gene therapy for retinal diseases market reports covers prominent players such as Applied Genetic Technologies Corporation, Adverum Biotechnologies, ProQR Therapeutics, MeiraGTx Limited., Oxford BioMedica, Horama S.A., Gensight Biologics, Regenxbio Inc., Spark Therapeutics, Inc., Genzyme (Sanofi), Novartis Pharmaceuticals, Nightstar Therapeutics (Biogen), Allergan, and Hemera Biosciences among others.
Curious about this latest version of report? Obtain Report Details @ https://www.insightaceanalytic.com/report-details/global-gene-therapy-for-retinal-diseases-market-assessment/
- Global Gene Therapy for Retinal Diseases Market by Indication Revenue (US$ Mn) Forecast 2020-2030
- Choroideremia (CHM)
- Leber congenital amaurosis
- Leber’s hereditary optic neuropathy
- X-linked retinitis pigmentosa
- Other Indication
- Global Gene Therapy for Retinal Diseases Market Based on Region Revenue (US$ Mn) Forecast 2020-2030
- Europe Revenue (US$ Mn) Forecast 2020-2030
- Rest of Europe
- North America Revenue (US$ Mn) Forecast 2020-2030
- Asia Pacific Revenue (US$ Mn) Forecast 2020-2030
- Rest of World Revenue (US$ Mn) Forecast 2020-2030
Why should buy this report:
- To receive a comprehensive analysis of the prospects for global gene therapy for retinal diseases market
- To receive industry overview and future trends gene therapy for retinal diseases market
- To analyze the gene therapy for retinal diseases market drivers and challenges
- To get information on gene therapy for retinal diseases market size value/revenue (US$ Mn) forecast till 2030
- Major Investments, Mergers & Acquisition in gene therapy for retinal diseases industry
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.